Clinical trial
A Single-arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Nimotuzumab as Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
NCT03766178 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single-arm, Open Phase II Clinical Trial of Anti-PD-1 Antibody SHR-1210 Combined With Nimotuzumab as Second-line Treatment of Advanced Esophageal Squamous Cell Carcinoma
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 30, 2021
- Completion date
- September 30, 2023
- Enrollment
- 45 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.